ICICI Securities: Increasing Competition For Generic Revlimid 
Tablets are arranged for a photograph. (Photographer: Kiyoshi Ota/Bloomberg)

ICICI Securities: Increasing Competition For Generic Revlimid 

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Securities Report

Cipla Ltd. has announced settlement of patent litigation with Celgene (subsidiary of Bristal Myers Squibb) for Revlimid (lenalidomide).

It has become the fourth company to have settled litigations pertaining to this product after Natco Pharma Ltd., Dr Reddy’s Laboratories Ltd. and Alvogen. Additional settlements with other companies also remain a possibility.

Revlimid’s brand sales in the U.S. stood at over six billion U.S. dollar in nine months-CY20.

We believe restriction on volume market share as per settlements will help minimise the impact of growing competition.

Click on the attachment to read the full report:

ICICI Securities Pharma Revlimid Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.